Compatibility Problems and Prescribing Pattern of Injectable Drugs at the Hospital
Drug safety is always a national, as well as international, patient safety goal. Administration of injection, especially intravenous infusion, is an extremely complicated and dangerous process, which includes reconstitution, dilution, selection of diluent and volume, verification of concentration of final solution, check for stability, sterility and compatibilities, and the selection of intravenous (IV) set, peripheral or central route, and the rate of infusion. Due to its inherent complexity, errors occur easily during these procedures. Literatures indicated that the incidence of injection administration errors ranged from 13% to 84%, which included errors in dosage, diluents, and volumes; excessive administration rate; and incompatible IV admixture.
In the U.S.A., pharmacists provide comprehensive clinical services. They ensure the appropriateness of every step in the process from prescription and dosage verification, drug reconstitution and dilution, selection of diluents and concentration, to the rate of administration. Even more, they provide the final IV products that are ready to administer to the patients (IV admixture services). Therefore, many common administration errors can be avoided. In Taiwan, nevertheless, pharmacists have limited role in IV services due to our health-care system. There are no studies on the administration pattern of injections. There is still room for improvement in the assurance of injection safety.
To ensure the safety of injection, we not only have to oversee the accuracy of drugs and dosage, but also take the compatibilities among drugs and diluents seriously.
Because diluent is not a mandatory claim data, the National Health Insurance data base cannot provide the related information for drug compatibility epidemiology study. The application for reimbursement of injections is based on total amount used instead of daily usage; it is therefore difficult to find drug incompatibility problems in this data base. Hospital data base analysis, questionnaire survey and chart review are more feasible for such study.
This study will analyze the prescriptions of IV injection in the intensive-care units and pediatric units to determine the prescribing pattern. High risk IV admixtures and Y-site administrations will be explored by questionnaire survey and literature review. Laboratory experiments will be done on some indicator drugs to find the reasons, categories and severities of the compatibilities. A list of incompatible drugs shall be generated for computerized intervention. We hope the results of the study can be used as a reference for guideline, policy and procedure for health care system and government.
調査の概要
状態
条件
研究の種類
入学 (実際)
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- nurses
Exclusion Criteria:
- not nurses
研究計画
研究はどのように設計されていますか?
デザインの詳細
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Drug incompatibility assessed by questionnaire survey
時間枠:6 months
|
IV admixture
|
6 months
|
協力者と研究者
捜査官
- 主任研究者:Taiwan National Taiwan University Hospital、National Taiwan University Hospital
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 200911016R
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
IV Injectionの臨床試験
-
Maastricht Radiation OncologyAmsterdam UMC, location VUmc完了
-
Jerome Canady, M.D.積極的、募集していないステージ IV の肺がん | IV期の膀胱がん | IV期の膵臓がん | 再発悪性固形新生物 | IV期乳がん | IV期の腎細胞がん | IV期前立腺がん | IV期結腸がん | IV期の直腸がん | IV期胃がん | IV期の非小細胞肺がん | IV期の結腸直腸がん | IV期肝がん | IV期の卵管がん | IV期の卵巣がん | IV期の小腸がんアメリカ
-
Niguarda HospitalUniversity of Turin, Italy; Fondazione del Piemonte per l'Oncologia完了
-
Peter SzmukLuminex Corporation; Outcomes Research Consortium完了
-
Asklepios proresearchMedical University of Vienna; Q1.6 B.V.まだ募集していません
-
Kilis 7 Aralik UniversityMersin University招待による登録
-
Fondazione Policlinico Universitario Agostino Gemelli...完了